IBS News

Subscribe to IBS News feed
IBS Patient Community - IBSpatient.org - IBS News
Updated: 1 hour 55 min ago

Pubmed-Gastrointestinal and Hepatic Disease in Fibromyalgia.

12 hours 50 min ago
Related Articles Gastrointestinal and Hepatic Disease in Fibromyalgia. Rheum Dis Clin North Am. 2018 Feb;44(1):131-142 Authors: Schatz RA, Moshiree B Abstract Fibromyalgia (FM) has historically been associated with several diseases in gastroenterology and hepatology. The most substantiated evidence pertains to irritable bowel syndrome (IBS). The pathogeneses of FM and IBS remain unclear, but it is likely related to dysregulation within the brain-gut axis, resulting in a hyperalgesic state. IBS and FM share other similarities, including a female predominance, fatigue, insomnia, and susceptibility to psychiatric state. These common manifestations and pathogeneses serve as a foundation for overlapping, multidisciplinary treatment modalities. PMID: 29149921 [PubMed - in process] View the full article

Google-8 Science-Backed Ways To Get Rid Of Bloat For Good - mindbodygreen.com

13 hours 23 min ago
mindbodygreen.com 8 Science-Backed Ways To Get Rid Of Bloat For Good mindbodygreen.com With gut disorders, that number turns out to be higher. Researchers find nearly everyone with irritable bowel syndrome (IBS) experiences bloating. In my practice, I find most patients with gut problems encounter some degree of bloating at some point in ... View the full article

Pubmed-Cross-organ sensitisation between the colon and bladder: To pee, or not to pee?

Nov 18, 2017
Cross-organ sensitisation between the colon and bladder: To pee, or not to pee? Am J Physiol Gastrointest Liver Physiol. 2017 Nov 16;:ajpgi.00272.2017 Authors: Grundy L, Brierley SM Abstract Chronic abdominal and pelvic pain are common, debilitating clinical conditions experienced by millions of patients around the globe. The origin of such pain commonly arises from the intestine and bladder, which share common primary roles; the collection, storage and expulsion of waste. These visceral organs are located in close proximity to one another, and also share common innervation from spinal afferent pathways. Chronic abdominal pain, constipation or diarrhoea are primary symptoms for patients with Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD). Chronic pelvic pain, urinary urgency and frequency are primary symptoms experienced by patients with lower urinary tract disorders such as interstitial cystitis/painful bladder syndrome (IC/PBS). It is becoming clear that these symptoms and clinical entities do not occur in isolation, with considerable overlap in symptom profiles across patient cohorts. Here we review recent clinical and experimental evidence documenting the existence of 'cross-organ sensitisation' between the colon and bladder. In such circumstances, colonic inflammation may result in profound changes to the sensory pathways innervating the bladder, resulting in severe bladder dysfunction. PMID: 29146678 [PubMed - as supplied by publisher] View the full article

Pubmed-An update on prucalopride in the treatment of chronic constipation.

Nov 18, 2017
An update on prucalopride in the treatment of chronic constipation. Therap Adv Gastroenterol. 2017 Nov;10(11):877-887 Authors: Omer A, Quigley EMM Abstract Chronic constipation (CC) is a highly prevalent and often under-appreciated gastrointestinal disorder associated with significant impairment in quality of life. Symptoms of constipation are typically present for a number of years prior to a patient seeking help. Lifestyle modifications followed by, or coupled with, over-the-counter laxatives represent the initial treatment option; however, relief for many is limited and dissatisfaction rates for these approaches remain high. Over recent years, therefore, considerable effort has been exerted on the development of novel pharmacological approaches. Two major targets have emerged, motility and secretion. Research on the former led to the development of a number of prokinetic agents capable of stimulating colonic motility and, thus, accelerating colonic transit. Of these, earlier prototypes such as cisapride and tegaserod, though effective, were ultimately withdrawn due to cardiovascular adverse events due in part to receptor non-selectivity. Highly selective serotonergic receptor agonists have since emerged which appear to be equally effective in stimulating gut motility but are devoid of cardiac side effects. One such agent is prucalopride, which has now been approved for the management of chronic idiopathic constipation in several countries, but not in the United States. Multiple multicenter, randomized placebo-controlled clinical trials have demonstrated superiority for prucalopride compared to placebo in the short to medium term in relieving the major symptoms of constipation in both men and women across a broad spectrum of ages, ethnicities and geographic locations. To date, prucalopride has enjoyed a favorable safety profile and there have been no signals to suggest arrythmogenicity. Efficacy over longer periods of treatment remains to be confirmed. Evidence for efficacy in other forms of constipation, such as opioid-induced constipation and that related to Parkinson's disease is beginning to emerge; its status in the management of constipation-predominant irritable bowel syndrome or foregut motility disorders, such as gastroparesis, remains to be established. PMID: 29147138 [PubMed] View the full article

Pubmed-Purinergic drug targets for gastrointestinal disorders.

Nov 18, 2017
Purinergic drug targets for gastrointestinal disorders. Curr Opin Pharmacol. 2017 Nov 14;37:131-141 Authors: Burnstock G, Jacobson KA, Christofi FL Abstract Purinergic receptors are implicated in the pathogenesis of gastrointestinal disorders and are being explored as potential therapeutic targets. Gut inflammation releases ATP that acts on neuronal, glial, epithelial and immune cells. Purinergic signalling in glia and neurons is implicated in enteric neuropathies. Inflammation activates glia to increase ATP release and alter purinergic signalling. ATP release causes neuron death and gut motor dysfunction in colitis via a P2X7-dependent neural-glial pathway and a glial purinergic-connexin-43 pathway. The latter pathway also mediates morphine-induced constipation and gut inflammation that may differ from opioid-induced constipation. P2X7R antagonists are protective in inflammatory bowel disease (IBD) models, where as AZD9056 is questionable in Crohn's disease, but is potentially beneficial for chronic abdominal pain. Drug targets under investigation for IBD, irritable bowel syndrome and motility disorders include P2X7R, P2X3R, P2Y2R, A2A/A2BAR, enzymes and transporters. PMID: 29149731 [PubMed - as supplied by publisher] View the full article

Google-Discovery Of New Tests & Causes For Fibromyalgia Could Offer Relief To Millions Of Sufferers - Bustle

Nov 17, 2017
Bustle Discovery Of New Tests & Causes For Fibromyalgia Could Offer Relief To Millions Of Sufferers Bustle Researchers at Massachusetts General Hospital have identified an underlying condition that could play a role in illnesses like chronic fatigue, fibromyalgia, and irritable bowel syndrome, according to a study published in the journal Current Pain and ... View the full article

Google-First RNA-Based Blood Test Available for IBS, IBD Diagnoses, IQuity Announces - IBD News Today

Nov 17, 2017
First RNA-Based Blood Test Available for IBS, IBD Diagnoses, IQuity Announces IBD News Today IQuity, a leading life science technology company in the field of RNA-based diagnosis, announced the release of IsolateIBS-IBD, a pioneering blood test that helps clinicians identify with great accuracy irritable bowel syndrome (IBS) or inflammatory ... View the full article

Google-Massachusetts researchers make major discovery about IBS, fibromyalgia - Atlanta Journal Constitution

Nov 17, 2017
Atlanta Journal Constitution Massachusetts researchers make major discovery about IBS, fibromyalgia Atlanta Journal Constitution Researchers at Massachusetts General Hospital have made a groundbreaking discovery that could ease symptoms for millions of people suffering from conditions such as chronic fatigue, fibromyalgia and irritable bowel syndrome. >> Read more trending ... and more » View the full article

Pubmed-Non-celiac gluten sensitivity: All wheat attack is not celiac.

Nov 17, 2017
Non-celiac gluten sensitivity: All wheat attack is not celiac. World J Gastroenterol. 2017 Oct 28;23(40):7201-7210 Authors: Igbinedion SO, Ansari J, Vasikaran A, Gavins FN, Jordan P, Boktor M, Alexander JS Abstract Currently, 1% of the United States population holds a diagnosis for celiac disease (CD), however, a more recently recognized and possibly related condition, "non-celiac gluten sensitivity" (NCGS) has been suggested to affect up to 6% of the United States public. While reliable clinical tests for CD exist, diagnosing individuals affected by NCGS is still complicated by the lack of reliable biomarkers and reliance upon a broad set of intestinal and extra intestinal symptoms possibly provoked by gluten. NCGS has been proposed to exhibit an innate immune response activated by gluten and several other wheat proteins. At present, an enormous food industry has developed to supply gluten-free products (GFP) with GFP sales in 2014 approaching $1 billion, with estimations projecting sales to reach $2 billion in the year 2020. The enormous demand for GFP also reflects a popular misconception among consumers that gluten avoidance is part of a healthy lifestyle choice. Features of NCGS and other gluten related disorders (e.g., irritable bowel syndrome) call for a review of current distinctive diagnostic criteria that distinguish each, and identification of biomarkers selective or specific for NCGS. The aim of this paper is to review our current understanding of NCGS, highlighting the remaining challenges and questions which may improve its diagnosis and treatment. PMID: 29142467 [PubMed - in process] View the full article

Pubmed-Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients with clinical remission.

Nov 17, 2017
Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients with clinical remission. Intest Res. 2017 Oct;15(4):543-545 Authors: Fukuba N, Ishihara S, Kawashima K, Mishima Y, Oshima N, Kinoshita Y PMID: 29142525 [PubMed] View the full article

Google-Sentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting ... - GlobeNewswire (press release)

Nov 17, 2017
Sentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting ... GlobeNewswire (press release) In the GI area, diseases of interest include irritable bowel syndrome (IBS), postoperative ileus (POI), postoperative nausea and vomiting (PONV), gastroparesis and cyclic vomiting syndrome (CVS). Astressins also provide a means to address certain ... and more » View the full article

Google-Global Irritable Bowel Syndrome Epidemiology and Patient Flow Analysis - 2017 - PR Newswire (press release)

Nov 16, 2017
Global Irritable Bowel Syndrome Epidemiology and Patient Flow Analysis - 2017 PR Newswire (press release) The report provides insights into Irritable Bowel Syndrome epidemiology, Irritable Bowel Syndrome diagnosed patients, and Irritable Bowel Syndrome treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence ... Irritable Bowel Syndrome Drugs Market Production, Consumption, Export and Import, Revenue, Price Trend by Type ...MilTech all 2 news articles » View the full article

Google-IBS -Associated Chronic Pain: Formulation of Core Diagnostic Criteria - Clinical Pain Advisor

Nov 16, 2017
Clinical Pain Advisor IBS -Associated Chronic Pain: Formulation of Core Diagnostic Criteria Clinical Pain Advisor An evidence-based framework was applied to the diagnosis of chronic abdominal, pelvic, and urogenital pain in patients with irritable bowel syndrome. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and ... View the full article

Pubmed-Effects of SCN9A gene modification on Na+ channel and the expression of nerve growth factor in a rat model of diarrhea‑predominant irritable bowel syndrome.

Nov 16, 2017
Related Articles Effects of SCN9A gene modification on Na+ channel and the expression of nerve growth factor in a rat model of diarrhea‑predominant irritable bowel syndrome. Mol Med Rep. 2017 Nov 14;: Authors: Cai YY, Li C, Yan ZX, Ma N, Li FF Abstract The aim of the present study was to identify whether the sodium voltage-gated channel alpha subunit 9 (SCN9A) gene modification is a potential treatment for diarrhea‑predominant irritable bowel syndrome (D‑IBS), via regulating the Na+ channel and the expression of nerve growth factor (NGF). The recombinant adenovirus vector of the SCN9A gene was established, and rat colon cells were isolated for SCN9A gene modification. All subjects were divided into four groups: i) The SCN9A‑modified (D‑IBS rat model implanted with SCN9A‑modified colon cells), ii) negative control (NC; D‑IBS rat model implanted with colon cells without SCN9A gene modification), iii) blank (D‑IBS rat model without any treatment) and iv) normal (normal rats without any treatment). Western blotting and reverse transcription‑quantitative polymerase chain reaction were used to detect the protein and mRNA expression levels of SCN9A, NGF and voltage gated sodium channels (Nav)1.8 and Nav1.9 in rat colon tissues. Compared with the normal group, the rats in the SCN9A, NC and blank groups had significantly elevated mRNA and protein expression levels of NGF, SCN9A, Nav1.8 and Nav1.9. The rats in the SCN9A group demonstrated significantly increased mRNA and protein expression levels of NGF, SCN9A, Nav1.8 and Nav1.9 compared with the NC group and the blank group (all P<0.05). SCN9A gene modification can promote the expression of Nav1.8 and Nav1.9 channels, in addition to NGF which may provide a novel therapeutic basis for treating of D‑IBS. PMID: 29138838 [PubMed - as supplied by publisher] View the full article

Pubmed-Blastocystis subtypes isolated from irritable bowel syndrome patients and co-infection with Helicobacter pylori.

Nov 16, 2017
Related Articles Blastocystis subtypes isolated from irritable bowel syndrome patients and co-infection with Helicobacter pylori. Parasitol Res. 2017 Nov 14;: Authors: El-Badry AA, Abd El Wahab WM, Hamdy DA, Aboud A Abstract Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disease presenting clinically by abdominal pain with alteration of bowel habits. Although IBS has uncertain etiology, chronic gut inflammation due to persistent exposure to an infectious agent including Blastocystis sp. was proposed. The aim of this study was to detect the prevalence of Blastocystis sp. subtype (ST) isolated from stool of IBS patients and to assess Blastocystis sp. and H. pylori co-infection in IBS patients from Beni-Suef Governorate, Egypt. Stool samples were collected from 115 IBS patients, following Rome III criteria. All stool samples were microscopically examined by wet mount and permanent trichrome stain, cultured on Jones' medium with further sequencing of positive Blastocystis isolates and screened for detection of H. pylori coproantigen. Blastocystis sp. was the predominant parasite in IBS patients; it had statistical significant association with both rural residence (OR = 10) and flatulence (OR = 8.2). There was a predominance of Blastocystis sp. ST3 (81%) followed by ST1 (19%). Blastocystis culture results (19.1%) were superior than microscopy (16.5%). The majority of Blastocystis-positive IBS patients (72.7%) were co-infected with H. pylori with statistical significance; however, H. pylori was higher in Blastocystis-negative IBS patients (47/64) than in Blastocystis-positive IBS patients (17/64). Interestingly, IBS is usually associated with gut dysbiosis, while the most prevalent parasite in our IBS patients was Blastocystis sp., which is frequently found in asymptomatic individuals. Whether Blastocystis sp. is a cause or a consequence of IBS still needs further investigation, with a particular focus on correlation of IBS with different Blastocystis sp. subtypes and gut microbiomes. PMID: 29138961 [PubMed - as supplied by publisher] View the full article

Google-Diets, medicine may help ease irritable bowl syndrome - WEAR

Nov 15, 2017
WEAR Diets, medicine may help ease irritable bowl syndrome WEAR (WEAR) — It's a condition that affects as many as 45 million Americans, and few of them want to talk about it. The symptoms of IBS, or irritable bowel syndrome, include excessive constipation, diarrhea, or both. Though IBS affects the quality of life ... View the full article

Google-Risk Factors for Small Intestinal Bacterial Overgrowth - News-Medical.net

Nov 15, 2017
News-Medical.net Risk Factors for Small Intestinal Bacterial Overgrowth News-Medical.net This may be due to slowing motility with age, the effects of medication, associated medical conditions such as Crohn's or irritable bowel syndrome, and metabolic disorders such as chronic diabetes. Dysmotility ... this finding. However, the association ... View the full article

Pubmed-Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment.

Nov 15, 2017
Related Articles Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Prim Care. 2017 Dec;44(4):655-671 Authors: Defrees DN, Bailey J Abstract Irritable bowel syndrome is a common medical condition that significantly alters patient quality of life and presents a series of diagnostic and treatment challenges to the treating provider. This article provides an updated and straightforward overview of the disease, its pathophysiology, diagnosis, and treatment options. PMID: 29132527 [PubMed - in process] View the full article

Pubmed-Celiac Disease and Gluten Sensitivity.

Nov 15, 2017
Related Articles Celiac Disease and Gluten Sensitivity. Prim Care. 2017 Dec;44(4):693-707 Authors: DeGeorge KC, Frye JW, Stein KM, Rollins LK, McCarter DF Abstract Celiac disease is an immune-mediated enteropathy triggered by gluten that affects genetically predisposed individuals, typically causing intestinal symptoms and malabsorption. Diagnosis requires stepwise evaluation with anti-tissue transglutaminase IgA and histologic analysis of the small bowel. Strict adherence to a gluten-free diet is the primary treatment. Patients with symptoms thought to be related to gluten but without evidence of celiac disease are difficult to diagnose and treat. Consider first advising general nutritional improvements. If symptoms persist, involve a trained dietitian for restrictive diets and consider evaluation for small intestinal bacterial overgrowth or other treatments for irritable bowel syndrome. PMID: 29132529 [PubMed - in process] View the full article

Pubmed-Medicinal Foods for Functional GI Disorders.

Nov 15, 2017
Related Articles Medicinal Foods for Functional GI Disorders. Curr Gastroenterol Rep. 2017 Nov 13;19(12):62 Authors: Acker BW, Cash BD Abstract PURPOSE OF REVIEW: Over the past 10 years, there has been a dramatic increase in basic and clinical research involving functional gastrointestinal disorders (FGIDs). New diagnostic and biomarker procedures are helping to identify physiologic disruptions associated with FGIDs on cellular and molecular levels. Simultaneously, clinicians are using new approaches to help manage patients with FGIDs. Among these, an important component of care has been the use of medical foods. These include probiotics, prebiotics, synbiotics, peppermint oil, caraway oil, curcumin, bovine immunoglobulin and many others. RECENT FINDINGS: The putative effects of different medical foods make these therapies attractive for the management of FGIDs. These include effects on several pathophysiological mechanisms such as anti-inflammatory, smooth muscle relaxation, analgesia, mitigation of gut barrier dysfunction, and stimulation or inhibition of gastrointestinal receptors. Recent research has also demonstrated the efficacy of medical food products such as peppermint oil and serum-derived bovine immunoglobulin for the management of irritable bowel syndrome. Older data supports the probiotic VSL#3 and Bifidobacterium species. For functional dyspepsia, positive effects have been observed with the combination of caraway seed oil and peppermint oil as well as with STW-5, a botanical combination preparation, although robust RCTs are lacking. With advancing knowledge regarding the pathogenesis of FGIDs, it is likely that the compounds available in the medical food category will increase dramatically, and they could play an important role in the management of several common and bothersome gastrointestinal conditions in the future. PMID: 29134293 [PubMed - in process] View the full article

Pages